Abstract and Introduction
Background: Perfluorooctanoic acid (PFOA, also known as C8) and perfluorooctane sulfonate (PFOS) are stable compounds with many industrial and consumer uses. Their persistence in the environment plus toxicity in animal models has raised concern over low-level chronic exposure effects on human health.
Objectives: We estimated associations between serum PFOA and PFOS concentrations and thyroid disease prevalence in representative samples of the U.S. general population.
Women exposed to perfluorinated chemicals (PFCs) are at increased risk of developing hypothyroidism, according to results from a large, population-based survey.
The study was published online July 17 in the Journal of Clinical Endocrinology & Metabolism.
October 31, 2011 (Indian Wells, California) — A significant increase in the incidence of thyroid cancer in recent decades might be largely attributable to cancers incidentally found with ultrasound and other types of imaging, according to research presented here at the American Thyroid Association 81st Annual Meeting.
An investigational agent may allow some patients with metastatic thyroid cancer to overcome resistance to radioiodine, according to a new report from researchers at Memorial Sloan-Kettering Cancer Center in New York.
The product, selumetinib (under development by AstraZeneca) is being investigated in a number of different cancer types.
In this study, it was investigated in 20 patients with thyroid cancer who had been treated with radioiodine, but who had become resistant to the treatment.
"Zealous" imaging is fueling the overdiagnosis and overtreatment of subclinical low-risk thyroid cancer in the United States, researchers warn in a new report.
"There has been an increase in low-risk thyroid cancer worldwide, but in the United States, the increase has been much more dramatic," said the report's first author, Juan P. Brito, MD, from the knowledge and evaluation research unit at the Mayo Clinic in Rochester, Minnesota.